A. Dugar

975 total citations · 1 hit paper
25 papers, 626 citations indexed

About

A. Dugar is a scholar working on Cellular and Molecular Neuroscience, Social Psychology and Clinical Psychology. According to data from OpenAlex, A. Dugar has authored 25 papers receiving a total of 626 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cellular and Molecular Neuroscience, 4 papers in Social Psychology and 4 papers in Clinical Psychology. Recurrent topics in A. Dugar's work include Child and Adolescent Psychosocial and Emotional Development (4 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (3 papers) and Neuroscience and Neuropharmacology Research (3 papers). A. Dugar is often cited by papers focused on Child and Adolescent Psychosocial and Emotional Development (4 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (3 papers) and Neuroscience and Neuropharmacology Research (3 papers). A. Dugar collaborates with scholars based in United States, Canada and United Kingdom. A. Dugar's co-authors include Michelle Stewart, Robert W. Buchanan, Richard S.E. Keefe, Nina R. Schooler, M. Zivkov, Stephen R. Marder, Jerry R. Mendell, Jonathan Davidson, Douglas E. Feltner and Joan M. Lakoski and has published in prestigious journals such as Neuroscience, Schizophrenia Bulletin and Investigative Ophthalmology & Visual Science.

In The Last Decade

A. Dugar

22 papers receiving 605 citations

Hit Papers

Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-d... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy
    2020 264 citations Jerry R. Mendell, Zarife Sahenk et al. JAMA Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Dugar United States 10 296 133 120 87 78 25 626
Tamar L. Ben-Shaanan Israel 9 209 0.7× 21 0.2× 137 1.1× 39 0.4× 92 1.2× 11 1.0k
P Bergonzi Italy 20 205 0.7× 185 1.4× 210 1.8× 94 1.1× 361 4.6× 58 922
Jianzhong Yang China 14 268 0.9× 229 1.7× 114 0.9× 27 0.3× 115 1.5× 50 770
Lucia Parisi Italy 14 143 0.5× 148 1.1× 193 1.6× 75 0.9× 285 3.7× 47 714
Shana E. Cyrulnik United States 7 270 0.9× 62 0.5× 70 0.6× 8 0.1× 84 1.1× 7 402
Herbert Schreiber Germany 21 332 1.1× 46 0.3× 200 1.7× 78 0.9× 409 5.2× 62 1.4k
Christoph Däpp Switzerland 11 213 0.7× 125 0.9× 94 0.8× 153 1.8× 110 1.4× 13 721
Elizabeth A. Lovejoy United Kingdom 6 227 0.8× 112 0.8× 152 1.3× 20 0.2× 73 0.9× 6 564
Paul Cernasov United States 11 78 0.3× 34 0.3× 55 0.5× 81 0.9× 114 1.5× 23 481
Tamar Green United States 20 632 2.1× 382 2.9× 147 1.2× 38 0.4× 286 3.7× 51 1.2k

Countries citing papers authored by A. Dugar

Since Specialization
Citations

This map shows the geographic impact of A. Dugar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Dugar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Dugar more than expected).

Fields of papers citing papers by A. Dugar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Dugar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Dugar. The network helps show where A. Dugar may publish in the future.

Co-authorship network of co-authors of A. Dugar

This figure shows the co-authorship network connecting the top 25 collaborators of A. Dugar. A scholar is included among the top collaborators of A. Dugar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Dugar. A. Dugar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Campbell, Craig, H. Phan, Perry B. Shieh, et al.. (2024). 225P Initial data from the DELIVER trial of DYNE-251 in males with DMD Mutations amenable to Exon 51 skipping. Neuromuscular Disorders. 43. 104441.67–104441.67.
3.
Dugar, A., et al.. (2024). Patient engagement in clinical trial design for rare neuromuscular disorders: impact on the DELIVER and ACHIEVE clinical trials. Research Involvement and Engagement. 10(1). 1–1. 4 indexed citations
4.
5.
Naylor, Martin, et al.. (2023). P45 A phase 1/2 study of DYNE-251 in males with DMD mutations amenable to exon 51 skipping: DELIVER study design. Neuromuscular Disorders. 33. S69–S70. 2 indexed citations
6.
Abdel‐Hamid, Hoda, Barry J. Byrne, Anne M. Connolly, et al.. (2021). A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. Journal of Neuromuscular Diseases. 9(1). 39–52. 31 indexed citations
7.
Mendell, Jerry R., Zarife Sahenk, Kelly J. Lehman, et al.. (2020). Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy. JAMA Neurology. 77(9). 1122–1122. 264 indexed citations breakdown →
8.
Keefe, Richard S.E., Robert W. Buchanan, Stephen R. Marder, et al.. (2012). Poster #199 CLINICAL TRIALS OF POTENTIAL COGNITIVE-ENHANCING DRUGS IN SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR?. Schizophrenia Research. 136. S352–S352. 1 indexed citations
9.
Dugar, A., et al.. (2012). Enhanced Chat Application. 12. 3 indexed citations
10.
Keefe, Richard S.E., Robert W. Buchanan, Stephen R. Marder, et al.. (2011). Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?. Schizophrenia Bulletin. 39(2). 417–435. 114 indexed citations
11.
Berger, Ariel, John Edelsberg, Vamsi Bollu, et al.. (2011). Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study. BMC Psychiatry. 11(1). 193–193. 9 indexed citations
12.
Berger, Ariel, John Edelsberg, Vamsi Bollu, et al.. (2011). Health Care Utilization and Costs in Patients with Generalized Anxiety Disorder Initiating Add-on Therapy with Benzodiazepines. 3(1). e45–e54. 1 indexed citations
13.
Davidson, Jonathan, Douglas E. Feltner, & A. Dugar. (2010). Management of Generalized Anxiety Disorder in Primary Care. The Primary Care Companion to The Journal of Clinical Psychiatry. 12(2). 46 indexed citations
14.
Vernon, Margaret, A. Dugar, Dennis A. Revicki, Michael Treglia, & Daniel J. Buysse. (2009). Measurement of non-restorative sleep in insomnia: A review of the literature. Sleep Medicine Reviews. 14(3). 205–212. 54 indexed citations
15.
Bakal, Jeffrey A., et al.. (2005). Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Canadian Journal of Ophthalmology. 40(3). 313–319. 37 indexed citations
16.
Dugar, A., et al.. (2004). A Comparison of Quality of Life in AMD Patients with Monocular versus Bilateral Disease. Investigative Ophthalmology & Visual Science. 45(13). 1381–1381. 1 indexed citations
17.
Sharma, Sanjay, Jeffrey A. Bakal, Gary C. Brown, Gaurav K. Shah, & A. Dugar. (2004). Economic Resources Utilized in a Cohort of Patients with Age–Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 45(13). 1410–1410. 1 indexed citations
18.
19.
20.
Maines, Lynn W., et al.. (1998). Age-dependent loss of corticosterone modulation of central serotonin 5-HT1A receptor binding sites. Journal of Neuroscience Research. 53(1). 86–98. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tamar L. Ben-Shaanan Breakdown of academic impact, for papers by P Bergonzi Breakdown of academic impact, for papers by Jianzhong Yang Breakdown of academic impact, for papers by Lucia Parisi Breakdown of academic impact, for papers by Shana E. Cyrulnik Breakdown of academic impact, for papers by Herbert Schreiber Breakdown of academic impact, for papers by Christoph Däpp Breakdown of academic impact, for papers by Elizabeth A. Lovejoy Breakdown of academic impact, for papers by Paul Cernasov Breakdown of academic impact, for papers by Tamar Green
Rankless by CCL
2026